Editor's Note: In 2023, significant progress has been made in the field of breast cancer research. Dr. Zefei Jiang from The Fifth Medical Center of Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article summarizes Professor Jiang's speeches and highlights key advances in breast cancer treatment in 2023.New Strategies for Treating HER2-Positive Breast Cancer
At the “2023 Summer Forum on Breast Cancer: Northern Salon,” Professor Jiang emphasized the importance of developing new drugs based on clinical value. He pointed out that the introduction of subcutaneous trastuzumab has effectively addressed many issues faced by HER2-positive breast cancer patients undergoing anti-HER2 therapy, such as cumbersome hospitalization processes, high risk of hospital-acquired infections, and long intravenous infusion times. Professor Jiang proposed that using different types of drugs or administration methods can extend patient survival and improve quality of life. He highlighted that subcutaneous administration shortens treatment time, allowing patients more personal time and improving treatment adherence.
Chronic Disease Management of Breast Cancer
In discussions at the Chinese Society of Clinical Oncology (CSCO), Professor Jiang stated that breast cancer has entered an era of chronic disease management. He emphasized that treatment should not only aim to extend survival but also improve quality of life for breast cancer patients. He advocated for optimizing treatment methods, such as switching from intravenous injections to oral or subcutaneous administrations, to enhance patient adherence to treatment. Professor Jiang also mentioned that managing breast cancer as a chronic disease requires the joint efforts of doctors, nurses, and patients’ families, as well as the use of artificial intelligence for individual case management to remind patients to continue their treatment.
International Cooperation and Academic Exchange
During the “CSCO-CBCS-JBCS High-Level Dialogue,” Professor Jiang, along with other experts in the field of breast cancer, discussed the characteristics and treatment standards of breast cancer in different populations. He stressed the importance of cooperation and communication between Chinese and Japanese breast cancer experts and expressed his hope to share the latest research findings through international academic exchanges to provide better diagnostic and treatment solutions for breast cancer.
Advances in Triple-Negative Breast Cancer Treatment
In his annual review, Professor Jiang reflected on the progress in the treatment of triple-negative breast cancer (TNBC). He mentioned that significant achievements have been made with immunotherapy and Trop-2 targeted therapy for TNBC. Both the KEYNOTE-522 and IMpassion 031 studies demonstrated that combining immunotherapy with chemotherapy can significantly improve survival outcomes for TNBC patients. Professor Jiang also noted that new ADC drugs such as DS-8201 (T-DXd) and SKB264 offer new hope for patients with advanced TNBC.
Conclusion
Dr. Zefei Jiang’s insights and research findings not only provide new directions for breast cancer treatment but also offer important guidance for clinical practice and scientific exploration. With continuous research and international cooperation, the prospects for breast cancer treatment will become even brighter.
Professor Zefei Jiang
Director of Oncology, Cancer Center of the General Hospital of the People’s Liberation Army Deputy Chairman of the Youth Expert Committee, Chinese Society of Clinical Oncology (CSCO) Member and Secretary-General, Oncology Expert Committee, Capacity Building and Continuing Education Center, National Health Commission Standing Member, Patient Education Expert Committee and Member, Breast Cancer Expert Committee, CSCO Member, Breast Cancer Professional Committee, Chinese Anti-Cancer Association (CBCS) Standing Member, Breast Disease Branch, Chinese Medical Health International Exchange Promotion Association Deputy Leader, Breast Cancer Diagnosis and Treatment Technology Promotion Group, China National Health Association Member, Breast Professional Committee, Chinese Research Hospital Association Deputy Chairman, Breast Health Science Popularization Expert Committee, Shanghai Science Popularization Volunteers Association Standing Member, Breast Cancer Expert Committee and Cancer Rehabilitation and Palliative Care Expert Committee, Shanghai Anti-Cancer Association Member, Breast Cancer Group, Surgery Branch, Shanghai Medical Association Class Leader, First Session of the Medical Star Plan, Shanghai Health Development Foundation Editorial Board Member of CA Chinese Edition and Chinese Medical Forum Oncology Edition Review Expert for Frontiers in Oncology, JNCC Youth Editorial Board Member, Chinese Journal of Oncology
